Astellas-Pfizer’s combination therapy halves risk of death in bladder cancer patients Reuters Oct 20, 2025 The therapy reduces tumor recurrence and death risk in bladder cancer patients
Pfizer and Astellas announce extended survival data from EV-302 trial in advanced urothelial cancer EP News Bureau Feb 11, 2025 Additional follow-up from the Phase 3 study shows sustained overall survival benefit of enfortumab vedotin and pembrolizumab…
Lupin receives tentative US FDA approval for Mirabegron ER Tablets EP News Bureau Jun 28, 2019 Lupin’s Mirabegron ER Tablets, 25 mg and 50 mg, is a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of…
